Which Bone-Modifying Agents Are Most Effective in Reducing Bone Loss in Women with Early and Locally Advanced Breast Cancer?-A Cochrane Review summary with commentary

Şen E. İ.

Journal of Musculoskeletal Neuronal Interactions, vol.24, no.4, pp.332-335, 2024 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 4
  • Publication Date: 2024
  • Doi Number: 10.1002/14651858.cd013451.pub2
  • Journal Name: Journal of Musculoskeletal Neuronal Interactions
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, MEDLINE
  • Page Numbers: pp.332-335
  • Keywords: Bisphosphonate, Bone Loss, Breast Cancer, Denosumab, Quality of Life
  • Istanbul University Affiliated: Yes

Abstract

The aim of this commentary is to discuss from a rehabilitation perspective the Cochrane Review “Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis”[1] by Adams et al.a, published by the Cochrane Breast Cancer Group. This Cochrane Corner is produced in agreement with Journal of Musculoskeletal and Neuronal Interactions by Cochrane Rehabilitation with views* of the review summary author in the “implications for practice” section.